Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 198

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Identification of germline genetic mutations in patients with pancreatic cancer

Open access
Salo‐Mullen, Erin E., O'Reilly, Eileen M., Kelsen, David P., Ashraf, Asad M., Lowery, Maeve A., Yu, Kenneth H., Reidy, Diane L., Epstein, Andrew S., Lincoln, Anne, Saldia, Amethyst, Jacobs, Lauren M., Rau‐Murthy, Rohini, Zhang, Liying, Kurtz, Robert C., Saltz, Leonard, Offit, Kenneth, Robson, Mark E., Stadler, Zsofia K. · 2015 · Cancer

Abstract

BACKGROUND: Pancreatic adenocarcinoma (PAC) is part of several cancer predisposition syndromes; however, indications for genetic counseling/testing are not well‐defined. In the current study, the authors sought to determine mutation prevalence and characteristics that are predictive of an inherited predisposition for PAC. METHODS: A total of 175 consecutive patients with PAC who underwent clinical genetics assessment at Memorial Sloan Kettering Cancer Center between 2011 and 2014 were identified. Clinical data, family history, and germline results were evaluated. RESULTS: Among 159 patients with PAC who pursued genetic testing, 24 pathogenic mutations were identified (15.1%; 95% confidence interval, 9.5%‐20.7%), including BRCA2 (13 mutations), BRCA1 (4 mutations), p16 (2 mutations), PALB2 (1 mutation), and Lynch syndrome (4 mutations). BRCA1/BRCA2 prevalence was 13.7% in Ashkenazi Jewish (AJ) patients (95 patients) and 7.1% in non‐AJ patients (56 patients). In AJ patients with a strong, weak, or absent family history of BRCA‐associated cancers, the mutation prevalence was 16.7%, 15.8%, and 7.4%, respectively. The mean age at the time of diagnosis in all mutation carriers was 58.5 years (range, 45‐75 years) compared with 64 years (range, 27‐87 years) in those not carrying a mutation (P = .02). Although BRCA2 was the most common mutation identified, no patients with early‐onset PAC (diagnosed at age ≤ 50 years) harbored a BRCA2 mutation and the mean age at diagnosis in BRCA2 carriers was equivalent to that of individuals who were not mutation carriers (P = .34). Mutation prevalence in patients with early‐onset disease (21 patients) was 28.6%, including BRCA1 (2 mutations), p16 (2 mutations), MSH2 (1 mutation), and MLH1 (1 mutation). CONCLUSIONS: Mutations in BRCA2 account for > 50% of patients with PAC with an identified susceptibility syndrome. AJ patients were found to have high BRCA1/BRCA2 prevalence regardless of personal/family history, suggesting that ancestry alone indicates a need for genetic evaluation. With the exception of BRCA2‐associated PAC, an inherited predisposition for PAC is associated with an earlier age at PAC diagnosis, suggesting that this subset of patients may also represent a population warranting further evaluation. Cancer 2015;121:4382–8. © 2015 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.29664

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 198

Metadata

Authors
Salo‐Mullen, E. E., O'Reilly, E. M., Kelsen, D. P., Ashraf, A. M., Lowery, M. A., Yu, K. H., Reidy, D. L., Epstein, A. S., Lincoln, A., Saldia, A., Jacobs, L. M., Rau‐Murthy, R., Zhang, L., Kurtz, R. C., Saltz, L., Offit, K., Robson, M. E., & Stadler, Z. K.
Venue
Cancer
Publisher
Wiley
Published
2015-10-06
Volume
121
Issue
24
Pages
4382-4388
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W1838826168
Cited by
198
References
6
FWCI
12.13
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Identification of germline genetic mutations in patients with pancreatic cancer. https://app.cochat.ai/papers/10.1002/cncr.29664
The paper
Salo‐Mullen, E. E., O'Reilly, E. M., Kelsen, D. P., Ashraf, A. M., Lowery, M. A., Yu, K. H., Reidy, D. L., Epstein, A. S., Lincoln, A., Saldia, A., Jacobs, L. M., Rau‐Murthy, R., Zhang, L., Kurtz, R. C., Saltz, L., Offit, K., Robson, M. E., & Stadler, Z. K. (2015). Identification of germline genetic mutations in patients with pancreatic cancer. Cancer. https://doi.org/10.1002/cncr.29664

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.